[The sensitivity of the urinary microbial flora in patients with different courses of pyelonephritis to well-known antibacterial agents and to the new preparation flurenizid]. / Chutlyvist' mikrobnoï flory sechi khvorykh z riznym perebihom piielonefrytu do vidomykh antybakterial'nykh zasobiv i novoho preparatu flurenizydu.

Positive dynamics was observed in clinical picture and laboratory tests with sensitive to flureniside originators of pyelonephritis. No side effects were noted. The results obtained permit regarding flureniside as a drug of choice to be used for etiotropic treatment of patients with pyelonephritis caused by a sensitive to this chemotherapeutic agent microorganisms.

[The results of a clinical trial of flurenizid in phthisiopulmonology practice]. / Rezul'taty klinichnoï flurenizydu u ftyziopul'monolohichnii praktytsi.

Flurenizide, a new home drug preparation, endowed with antituberculosis activity, was administered to 20 patients with freshly detected pulmonary tuberculosis, in combination with etambutole or rifampycin in a daily dose of 0.6 g. After the above chemotherapy, closure of the cavities, diminution in size and consolidation of the foci as well as infiltrates, dispelling of the symptoms of intoxication, and discontinuance of bacteria discharge were observable in 70.0 percent of the cases. The drug is well tolerated by patients and is not associated with side effects. The results obtained permit recommending flurenizide for use in phthisiopulmonological practice.